Pooling nine trials (584 participants) with extractable brachial artery data, eicosapentaenoic acid produced a non-significant 0.47% gain in flow-mediated dilation (95% CI -0.24 to 1.18; I2 = 67.5%). Across 24 publications, effects varied by measurement method: plethysmographic forearm studies mostly showed improvement, while reactive hyperaemia index results were largely neutral. Exploratory subgroup tests pointed to treatment duration and EPA-alone formulation as possible modifiers, but not dose.
The headline is a null result with wide uncertainty, and that matters because EPA's cardiovascular reputation rests heavily on the REDUCE-IT trial, which used 4 g/day of icosapent ethyl and cut major events. Endothelial function was a plausible mechanism for that benefit, and this analysis fails to confirm it as a reliable, measurable effect. A pooled FMD gain under 0.5 percentage points is small next to the roughly 1% change associated with meaningful risk differences, and the confidence interval spans zero. High heterogeneity weakens any firm conclusion. The duration and formulation signals deserve skepticism: the authors acknowledge those subgroups rested on three studies sharing population, dose and design, and the tests were post hoc. FMD itself is operator-dependent and a surrogate, not an outcome. For adults, this offers no reason to expect vascular tuning from over-the-counter fish oil, and no basis to abandon prescription EPA where a clinician has indicated it for high triglycerides and established risk. Editorially, this is confirmatory of a mixed picture: a tempering of mechanistic enthusiasm rather than a challenge to outcome-trial data.